ReviewFrontiers in molecular biosciences2020
Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.
Review in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.International journal of molecular sciences · 2023Review
- GDF15 : A modulator of immunity and a predictive biomarker of cardiovascular events : A strategy in COVID-19.Annales de cardiologie et d'angeiologie · 2023Article
- An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).Expert opinion on drug discovery · 2022Review
- Indomethacin-based PROTACs as pan-coronavirus antiviral agents.European journal of medicinal chemistry · 2021Article
- GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism.Trends in endocrinology and metabolism: TEM · 2021Review
- Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS.Pharmaceutics · 2021Article
- Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection.International journal of molecular sciences · 2021Review
- Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.Virology journal · 2021Article
- Perspectives on RNA Vaccine Candidates for COVID-19.Frontiers in molecular biosciences · 2021Review
- Inhibition of SARS-CoV-2 3CL MFrontiers in molecular biosciences · 2021Article
- Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.Frontiers in molecular biosciences · 2021Review
- Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19.Frontiers in molecular biosciences · 2021Review
- Potential for Protein Kinase Pharmacological Regulation inInternational journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease-19 (COVID-19) is caused due to the infection by a unique single stranded enveloped RNA virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The COVID-19 has claimed many lives around the globe, and a promising solution to end this pandemic is still awaited. Till date neither an exact antiviral drug nor a vaccine is available in the market for public use to cure or control this pandemic. Repurposed drugs and supportive measures are the only available treatment options. This systematic review focuses on different treatment strategies based on various clinical studies. The review discusses all the current treatment plans and probable future strategies obtained as a result of a systematic search in PubMed and Science Direct database. All the possible options for the treatment as well as prophylaxis of COVID-19 are discussed. Apart from this, the article provides details on the clinical trials related to COVID-19, which are registered under ClinicalTrials.gov. Potential of drugs based on the previous researches on SARS-CoV, MERS-CoV, Ebola, influenza, etc. which fall under the same category of coronavirus are also emphasized. Information on cell-based and immunology-based approaches is also provided. In addition, miscellaneous therapeutic approaches and adjunctive therapies are discussed. The drug repurposing options, as evidenced from various
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.